Literature DB >> 9690966

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

C A Tamminga1, R W Buchanan, J M Gold.   

Abstract

Schizophrenia is a lifelong illness, with symptoms beginning in late adolescence/early adulthood and persisting throughout the rest of the patient's life. Positive psychotic symptoms may fluctuate during the course of the illness, but negative symptoms, especially primary negative symptoms, and cognitive dysfunction are relatively constant. The negative symptoms of schizophrenia are both primary (associated with the illness) and secondary (due to depression, neuroleptic-induced parkinsonism or acute psychosis). While secondary negative symptoms may be reduced by treating the causative agent, primary negative symptoms are viewed as enduring, persisting between psychotic episodes. Conventional antipsychotics treat the positive symptoms of schizophrenia, but they have little effect on primary negative and cognitive symptoms. Primary negative symptoms are often associated with poor premorbid function, the male sex, and low IQ (Intelligence Quotient). In addition, most studies find that negative symptoms are associated with a poor overall outcome. Several studies, including our own, have suggested that primary negative symptoms are functionally localized to the frontal and parietal cortices. These kinds of data raise the possibility that primary negative symptoms may have a pathophysiological basis distinct from positive psychosis. Cognitive impairment also appears to be a relatively independent aspect of schizophrenia. Impairment may be evident in a subtle form from early childhood, and often precedes the development of psychotic symptoms. Additional impairment accrues with the onset of psychotic illness with little evidence, in the vast majority of cases, of progression over the course of the illness. Cognitive impairment is only modestly related to psychotic symptom severity and type. However, the extent, and perhaps specific types of cognitive impairment, appear to be predictive of functional outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690966     DOI: 10.1097/00004850-199803003-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  37 in total

Review 1.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

2.  Probing the Dynamic Updating of Value in Schizophrenia Using a Sensory-Specific Satiety Paradigm.

Authors:  James A Waltz; Jaime K Brown; James M Gold; Thomas J Ross; Betty J Salmeron; Elliot A Stein
Journal:  Schizophr Bull       Date:  2015-04-01       Impact factor: 9.306

3.  The stress process perspective and adaptation of people with schizophrenia--an exploratory study.

Authors:  Yves Lecomte; Céline Mercier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

4.  Loss of asymmetric spine synapses in dorsolateral prefrontal cortex of cognitively impaired phencyclidine-treated monkeys.

Authors:  John D Elsworth; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-27       Impact factor: 5.176

5.  Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine.

Authors:  John D Elsworth; Bret A Morrow; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Neuropsychopharmacology       Date:  2011-06-15       Impact factor: 7.853

Review 6.  Brain rhythms connect impaired inhibition to altered cognition in schizophrenia.

Authors:  Benjamin R Pittman-Polletta; Bernat Kocsis; Sujith Vijayan; Miles A Whittington; Nancy J Kopell
Journal:  Biol Psychiatry       Date:  2015-02-14       Impact factor: 13.382

Review 7.  Promise and pitfalls of animal models of schizophrenia.

Authors:  David Feifel; Paul D Shilling
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

8.  Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders.

Authors:  Yu-Chen Kao; Yia-Ping Liu
Journal:  BMC Psychiatry       Date:  2010-08-18       Impact factor: 3.630

Review 9.  [Functional magnetic resonance tomography in patients with schizophrenia: neural correlates of symptoms, cognition and emotion].

Authors:  T Kircher; D Leube; U Habel
Journal:  Nervenarzt       Date:  2009-09       Impact factor: 1.214

10.  Impaired cerebellar-dependent eyeblink conditioning in first-degree relatives of individuals with schizophrenia.

Authors:  Amanda R Bolbecker; Jerillyn S Kent; Isaac T Petersen; Mallory J Klaunig; Jennifer K Forsyth; Josselyn M Howell; Daniel R Westfall; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Bull       Date:  2013-08-20       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.